Ipsen today announced that the U.S. FDA provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin (botulinum toxin of type A) Biologics License Application (BLA) in aesthetic indications (glabellar lines) has been extended to April 13, 2009.
The details can be read here.
No comments:
Post a Comment